Sarah Gheuens - 09 Jul 2025 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role
Chief Medical Officer
Signature
/s/ William Cook, as attorney-in-fact for Sarah Gheuens
Issuer symbol
AGIO
Transactions as of
09 Jul 2025
Net transactions value
-$154,632
Form type
4
Filing time
11 Jul 2025, 16:59:12 UTC
Previous filing
02 Jul 2025
Next filing
29 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gheuens Sarah Chief Medical Officer 88 SIDNEY STREET, CAMBRIDGE /s/ William Cook, as attorney-in-fact for Sarah Gheuens 11 Jul 2025 0001881190

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGIO Common stock Options Exercise $297,969 +11,914 +19% $25.01 73,185 09 Jul 2025 Direct
transaction AGIO Common stock Sale $419,771 -11,067 -15% $37.93 62,118 09 Jul 2025 Direct F1, F2
transaction AGIO Common stock Sale $32,830 -847 -1.4% $38.76 61,271 09 Jul 2025 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGIO Stock options (right to buy) Options Exercise $0 -11,914 -27% $0.000000 32,086 09 Jul 2025 Common stock 11,914 $25.01 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $37.52 to $38.49. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3 The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $38.55 to $38.87. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4 This option was originally granted on March 1, 2023 for the purchase of 44,000 shares of common stock. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter.